Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer

Nicholas A. Pease,1 Trisha Wise-Draper,2 and Lisa Privette Vinnedge1

1Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
2Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

Correspondence should be addressed to Lisa Privette Vinnedge; lisa.privette@cchmc.org

Received 2 January 2015; Accepted 5 March 2015

Academic Editor: Valentina Di caro

Copyright © 2015 Nicholas A. Pease et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is a long-standing correlation between inflammation, inflammatory cell signaling pathways, and tumor formation. Understanding the mechanisms behind inflammation-driven tumorigenesis is of great research and clinical importance. Although not entirely understood, these mechanisms include a complex interaction between the immune system and the damaged epithelium that is mediated by an array of molecular signals of inflammation—including reactive oxygen species (ROS), cytokines, and NFκB signaling—that are also oncogenic. Here, we discuss the association of the unique DEK protein with these processes. Specifically, we address the role of DEK in chronic inflammation via viral infections and autoimmune diseases, the overexpression and oncogenic activity of DEK in cancers, and DEK-mediated regulation of NFκB signaling. Combined, evidence suggests that DEK may play a complex, multidimensional role in chronic inflammation and subsequent tumorigenesis.

1. Introduction

Chronic inflammation has been linked to cancer for decades with several epidemiologic reports suggesting causation. In fact, several infectious and noninfectious known causes of cancer, such as viral infection (human papilloma virus, HPV, and Epstein Barr virus, EBV), Helicobacter pylori infection, smoking, and asbestos exposure to name a few, can induce inflammation prior to tumor formation. Additionally, upregulation through polymorphisms of the proinflammatory cytokines, tumor necrosis factor (TNF), and interleukin-1 (IL-1) has been associated with poor prognoses and disease severity in non-Hodgkin’s lymphoma and gastric cancer, respectively [1, 2]. Conversely, administration of known anti-inflammatory medications and herbs such as nonsteroidal anti-inflammatory drugs (NSAIDs), curcumin, and ginseng has been associated with a decreased risk of cancer, leading to several clinical studies investigating these agents as possible adjunct treatments [3–5]. However, the exact mechanisms of causation have remained unclear and in some instances, anti-inflammatory medications have been associated with a higher risk of cancer, making the association more complicated than initially proposed [6].

In general, inflammation and innate immunity are felt to be protumorigenic whereas adaptive immunity is antitumorigenic. In fact, tumor associated macrophages (TAMs), which are recruited during the inflammatory response, are indicators of a poor prognosis when identified in tumor tissue [7] while high levels of cytotoxic T (CD8+) cells, as part of adaptive immunity, correlate with a good prognosis [8, 9]. However, the presence of T cells in the microenvironment of tumors alone may not be sufficient to confer an immune response as they often are not active in recognizing the tumor as nonself. Therefore, a focus on negative regulators of the immune system, such as T regulatory (Treg) cells and other inhibitory molecules, is under investigation as a possible explanation for tumor immune escape. Multiple immune checkpoint molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and “programmed death-1” (PD-1) and its ligands (PD-L1 and PD-L2) are upregulated during the immune response in an attempt to prevent autoimmune damage to normal tissue. However, PD-1 is also induced
on T cells after activation by immune stimulation, either by infection or by tumor progression and, therefore, is felt to be a mechanism of immune resistance. Additionally, high levels of PD-1 in the tumor microenvironment and PD-1 ligand (PD-L1) expression have been found in many tumors and are correlated with poor prognoses in multiple tumor types [10–13]. Targeting of these pathways has proved to be exciting and effective, resulting in FDA approval of several agents (ipilimumab, nivolumab, and pembrolizumab) for melanoma with expectations for approval for other tumors in the near future [14–16]. However, not all tumors respond to these immune therapies, requiring a better understanding of the mechanism of failure and the complex interactions of the immune response to tumors.

Several proinflammatory cytokines and chemokines such as IL-1, IL-6, TNF, and IL-8 are often upregulated in response to cancer and are associated with tumor development and progression in mice [17]. Interestingly, it has been demonstrated that the classical IKK-β-dependent NFκB pathway may be the link between inflammation and cancer as activation results in upregulation of proinflammatory cytokines as well as several antiapoptotic factors [18]. Targeting the NFκB pathway may, therefore, be another promising approach to antitumor therapy either alone or in combination with traditional therapies or checkpoint blockade.

2. DEK Structure and Functions

One protein recently found to control NFκB activity is the DEK oncogene. DEK is a highly conserved chromatin-associated, nonhistone phosphoprotein (43 kDa) that was originally identified as part of a fusion protein (DEK-CN) in an acute myeloid leukemia (AML) subtype with translocation t(6;9), a balanced translocation, which confers a poor prognosis [19–21]. The presence of DEK in vitro was originally noted for its ability to partially correct cell sensitivity to mutagens and radiation in ATM-deficient fibroblasts [22]. Although it has no known enzymatic activity nor known homologs, it dynamically interacts with RNA, DNA, chromatin, and associated proteins to alter transcription, mRNA processing, DNA replication and repair, and chromatin topology [23–27]. DEK has three DNA binding domains: a central SAF-box, pseudo-SAF/SAP-box, and a C-terminal unique binding domain. The SAF-box domain enables DEK to preferentially bind cruciform and four-way junction structures and induce positive supercoiling; however, the C-terminal binding domain can facilitate DNA-DEK-DEK interactions that may facilitate regulatory processes [20, 28–30].

Nonetheless, other DEK domains participate in important molecular functions. Specifically, the acidic domains of DEK bind chromatin-bound histones and prevent optimal PCAF and p300-mediated histone acetyltransferase activity (HAT). This causes hypocetylation of DEK-bound regions of nucleosomes and can result in inhibition of HAT-mediated transcriptional activation [31]. Also, the physical interaction between DEK with Daxx and HDACII can assist in transcriptional repression by promoting histone deacetylation [25]. Additional structure-function studies have identified the SAP domain for its importance in DEK function. When the SAP domain of DEK interacts with casein kinase 2 (CK2) in the presence of ATP, DEK is phosphorylated. This DEK-CK2 complex displays an affinity for histone H3.3, a histone variant associated with active chromatin, and limits its placement on chromatin by protecting it from other potential histone chaperones that redistribute H3.3 in a DAAAX/ATRX-dependent manner from PML nuclear bodies [32, 33]. Furthermore, DEK is also necessary for optimal binding of heterochromatin protein 1-α (HP1-α) to the repressive chromatin mark, H3K9me3. This interaction facilitates silencing loops that prevent histone acetylation and protect heterochromatin integrity [34]. Finally, DEK binding to chromatin was found to limit access of the transcriptional machinery to chromatin, which could be disrupted by PARP1 and another histone chaperone, SET [35]. These functions suggest that DEK has the capacity to modify chromatin, via regulating histone acetylation and placement, in a manner that silences the expression of particular regions while also promoting general genomic stability.

However, it is also worth mentioning that some reports indicate that DEK can function as a positive transcriptional cofactor to induce gene expression [33, 36, 37]. In Drosophila, DEK was associated with more transcriptionally active regions of chromatin and coactivated the nuclear ecdysone receptor, promoting its functions as a transcriptional activator [33]. In murine breast tumor models, DEK also drives expression of Wnt ligands, resulting in the promotion of β-catenin transcriptional activity, which has also been noted in human breast cancer cells [38, 39]. Chromatin immunoprecipitation sequencing (ChIP-Seq) results have also revealed that DEK preferentially binds areas of euchromatin near transcription start sites of highly expressed genes, many of which include motifs for common transcriptional regulators such as SPI and RNA polymerase II [37].

Although the specific physical interactions are unknown, the molecular functions of DEK also extend to roles in DNA damage and stress response. DEK expression is necessary for proper DNA-PK mediated recruitment of DNA damage repair proteins Ku70/80 during nonhomologous end-joining (NHEJ) and prevents DNA damage accumulation that results in ATM mediated apoptosis [40]. This also supports evidence of DEK complementation in ataxia-telangiectasia cells, in which DEK fragments remedied the DNA damage phenotypes of ATM deficient fibroblasts [22]. DEK overexpression can also cause the destabilization of p53, resulting in the inhibition of normal p53-dependent apoptosis in cancer cells [41]. DEK also has a role in preventing p53-independent apoptosis by promoting the transcription of MCL-1, an antiapoptotic member of the BCL-2 family [42].

The molecular functions of DEK can be regulated by an array of protein modifications. Phosphorylation of DEK by CK2 weakens DEK-DNA binding [43] and has been linked to the secretion of DEK [44]. Other modifications that change DEK localization and function include acetylation by p300 [45], poly(ADP-ribosyl)ation by PARP1 [46], and truncation by DPP4 [47]. These posttranslational modifications of DEK are crucial for understanding the molecular functions that could contribute to pathogenesis. Phosphorylation by CK2...
and poly(ADP-ribosylation) by PARP1 can induce the release of DEK from chromatin, enabling it to function beyond chromatin remodeling [35]. Nonchromatin bound DEK can contribute to mRNA splicing events by interacting with the serine/arginine repeats of splicing complexes, while phosphorylation of DEK serines enables it to associate with U2AF and facilitate intron excision; there is evidence that the role of DEK in mRNA splicing may play a role in alternative splicing events of transcripts from genes such as tropomyosin TPM1 [48–51]. The function of DEK in the cytoplasm, if present, has not been determined; however, there are several different functions for DEK as a secretory molecule. These include inducing white blood cell migration as a chemotactrant [36], interacting with anti-DEK antibodies that trigger autoimmune responses [52], and possibly promoting chromatin remodeling and prosurvival functions by being taken up by neighboring cells [53]. Interestingly, it is currently unknown what conditions induce the posttranslational modifications of DEK that result in its delocalization from chromatin and secretion, resulting in pathological activities.

The ubiquitous and pleiotropic nature of DEK mandates that the expression and modification of DEK are tightly regulated in order to avoid pathology. The dysregulation of DEK can disturb normal cell functions and potentiate pathogenesis resulting in transformation, chemoresistance, inflammation, and tumor development. In this review, we postulate that DEK may be a crucial link between inflammation and tumorigenesis. We will discuss the role of DEK in viral infection and epitope presentation, which may provide mechanisms for both promoting intracellular viral oncogenesis and for eliciting T cell mediated immune responses that induce proinflammatory cytokines. These cytokines, such as IL-8, can further contribute to chronic inflammation, promote growth signaling in neighboring cells, and stimulate DEK secretion by macrophages. As a secretory molecule, DEK can be recognized by anti-DEK antibodies or be taken up as a functional exogenous protein by neighboring cells. The first function can exacerbate chronic inflammation and induce more proinflammatory factors that create favorable tumor microenvironments. The second secretory DEK function allows for excess DEK to amplify its numerous functions in cancer cells, it is no surprise that DEK expression causes dramatic apoptosis or senescence and can reduce ΔNp63 mediated cell growth [38, 41, 64, 82]. Deks−/− mice also demonstrate greatly diminished tumor formation, growth, and metastasis in both genetic and chemically induced tumorigenesis models [39, 64, 82]. Given its numerous functions in cancer cells, it is no surprise that DEK expression could be used as a biomarker for colorectal and bladder cancers and possibly other solid tumors as well [63, 83]. Of future clinical importance, RNA interference-mediated loss of DEK expression causes dramatic apoptosis or senescence of cancer cells whereas differentiated and nontransformed cells remain relatively unharmed [41, 79, 82].

In addition to gene amplification and overexpression in cancers, DEK expression and secretion are also induced in response to inflammation. In BEAS-2B human bronchial epithelial cells, DEK mRNA was upregulated in response to exposure to TiO2 particles, which are fine particles found in industrial workplaces that are known to cause airway inflammation and respiratory symptoms in both acute and chronic exposure situations [84]. In addition, microarray analyses of livers from rats fed crude fish oil, which contained high levels of persistent organic pollutants, showed moderately elevated DEK expression [85]. In rodents, prolonged exposure to persistent organic pollutants has been shown to cause insulin resistance and was associated with chronic low-grade inflammation [85, 86]. Although the molecular mechanism for this transcriptional regulation is unknown,
DEK upregulation in response to inflammatory signals is supported by the presence of multiple putative AP-1 (c-Fos/c-Jun), Ets-1, NF-AT, NFκB, STAT4, and C/EBP-β transcription factor consensus binding sites in the DEK promoter, which are known downstream transcription factors induced by proinflammatory signals (data not shown) [87–89]. Furthermore, secretion of phosphorylated DEK by monococyte-derived macrophages (MDM) is induced by the proinflammatory chemokine interleukin-8 (IL-8) where it becomes a chemotactic factor, attracting neutrophils, CD8+ T lymphocytes, and natural killer cells [44]. Immunosuppressive agents, such as dexamethasone and cyclosporine A, could block the secretion of DEK in MDM cells. This suggests that DEK expression, modification, and secretion are induced during inflammation, possibly to mediate cell survival, transcriptional responses, and/or migration of immune cells, which can ultimately result in transformation due to the intracellular oncogenic functions of DEK.

4. The Role of DEK during Infection with Cancer-Associated Viruses

Viral infection results in an inflammatory response and many cancers are known to be driven by oncogenic viruses. Examples of cancers linked to viral infection include cervical and other anogenital cancers, oropharyngeal carcinomas, hepatocellular carcinomas, Kaposi’s sarcomas, lymphomas, and T cell leukemia. In many instances, oncogenesis is thought to result from persistent, latent infections in which cell signaling processes are perturbed by either viral proteins or the chronic activation of inflammatory processes.

Cervical cancer and, more recently, head and neck cancer have been found to be associated with human papillomavirus (HPV) infection [90, 91]. Although HPV infection is quite common, in many individuals, the immune system clears the virus. However, in a select few, viral infection becomes persistent likely through the inability of infected cells to present antigenic epitopes to the host’s adaptive immune system [92]. Upon additional multiple mutations and carcinogenic events often linked to the viral life cycle, some of these chronically infected individuals will develop epithelial carcinomas. Although in normal HPV infection viral DNA remains episomal, in cancer, HPV is often found to be integrated into the host DNA. Integration leads to loss of the normal viral repressor HPV E2 resulting in uninhibited expression of the viral oncogenes E6 and E7. HPV E6 causes degradation of the tumor suppressor p53 while HPV E7 causes inhibition of the retinoblastoma (Rb) family of proteins, effectively halting major tumor suppressor pathways. Expression of HPV E6 and HPV E7 is required for maintenance of the malignant phenotype. Interestingly, DEK was found to be upregulated by HPV E7 and the suppression of DEK in HPV infected cells resulted in senescence [79, 93]. Additional studies demonstrated that DEK was an E2F transcription factor target gene, explaining its upregulation in response to retinoblastoma protein inhibition by E7 [66]. Dek knockout (Dek−/−) mice are resistant to HPV E6 and HPV E7 driven squamous cell carcinomas, supporting a critical role for DEK function in HPV-induced tumors [64]. Furthermore, DEK mRNA and protein upregulation are present in both cervical and head and neck cancer specimens, further supporting the importance of continued DEK expression in these cancers [59, 79, 94]. Even more intriguing is that although HPV tumors often carry a higher metastatic potential, HPV+ head and neck cancers confer a better prognosis than their HPV− counterparts, due to enhanced responses to treatment [95, 96]. Some have argued that the adaptive immune response associated with HPV infection is the reason for better responses to therapy [97].

Similar to HPV infection, DEK expression is also differentially regulated during EBV infections [98]. DEK was one of three genes differentially regulated across two EBV+ tumor types and also differentially regulated between nasopharyngeal carcinoma cells with latent and recurrent EBV infections. DEK expression was downregulated in recurrent EBV-infected cells but upregulated in latent EBV-infected nasopharyngeal carcinoma (NPC) cells. This provides evidence for DEK as a potential viral oncogenic mediator that links EBV latency-reactivation dynamics and cell transformation [98]. This may be the result of a well-documented latent infection response mediated by the Rb-controlled activity of E2F, a known activator of DEK expression [66, 99]. This CDK2-Rb/E2F-DEK pathway may be a crucial step in EBV-associated transformation of epithelial cells as seen in EBV+ NPC. Furthermore, small DNA tumor viruses, like HPV and EBV, exhibit a common molecular mechanism to inhibit the Rb family of proteins, especially pRb, to drive cellular proliferation, viral replication, and eventually oncogenesis. Therefore, DEK upregulation is likely a common event in virally induced tumors.

In addition to being transcriptionally regulated in response to viral infection, DEK also controls the use and maintenance of viral genetic material during human immunodeficiency virus (HIV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) infections. Although HIV is not oncogenic, the immune suppression and chronic inflammation it causes dramatically increases the risk of cancer due to coinfection with oncogenic viruses like KSHV, EBV, Hepatitis B and C viruses, and HPV. In addition to binding euchromatic chromatin, DEK also has unique binding properties that facilitate the use or maintenance of viral genetic material. In the case of HIV, DEK can bind to specific sequences of HIV-2 enhancer regions. These sequences, peri-ets (pets) sites, are one of several different cis-acting elements of the HIV-2 enhancer that stimulates transcription of viral genes in activated T lymphocytes. Within the HIV-2 enhancer region, the pets site contains a TTGGTCAGGG sequence that is found between the two Elf-1 binding sites, PuB1 and PuB2 [100]. DEK specifically binds these pets sites in human T lymphocytes, suggesting that DEK can regulate HIV-2 transcription and may be a downstream effector of T cell receptor activation [24]. Further investigation revealed that, upon phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment to activate T cells, DEK is replaced on the pets site, in a protein phosphatase-2A (PP2A) dependent manner, with another factor to induce HIV-2 promoter activation.
The process is stymied by PKC inhibitors and/or PP2A inhibitors (such as Okadaic acid), suggesting that PKC mediates the catalytic activity of PP2A, which alters the stability or DNA-binding activity of DEK, possibly via dephosphorylation. This change activated HIV-2 LTR and promotes HIV-2 transcription, assisting in the maintenance of HIV-2 infections [101]. However, it is unclear if the same mechanism exists in HIV-1 infected cells because Okadaic acid, which permits DEK retention on the pets sites and inhibits HIV-2 transcription, actually activates HIV-1 transcription.

While the presence of DEK in HIV-infected cells primarily controls viral transcriptional activity in T lymphocytes, the presence of DEK in two herpesvirus family infections (EBV and KSHV) has more implications on the occurrence of viral oncogenesis. In both cases, the virus must maintain genetic material during latency but also ensure that viral genomes are passed during mitosis. In KSHV infections, the latency-associated nuclear antigen (LANA) facilitates the association between mitotic chromosomes and viral genomes so that viral genomes are distributed to host daughter cells during latent infections [102]. Two studies have documented LANA-DEK binding that could have implications on KSHV infections and associated oncogenesis. Verma et al. demonstrated that DEK interacts with LANA in vitro [103]. Through GST affinity and immunoprecipitation assays, Krithivas et al. determined that DEK binds to the C-terminus of LANA and that a GFP-DEK fusion protein can be seen specifically localized to chromosomes of mouse cells [102]. These studies suggest that DEK-LANA interactions provide a secondary tethering opportunity for KSHV genomes that enable KSHV latency and DEK-driven oncogenesis. Combined, DEK is an important cellular protein that can regulate the transcription and retention of viral genomes while promoting proliferation to facilitate the viral life cycle. Nonetheless, it is unclear what links these persistent viral infections that require or increase DEK expression and the host's inflammatory responses to the viruses.

5. DEK Is an Autoantigen in Inflammatory Autoimmune Diseases and Cancer

Nearly two dozen autoimmune diseases have been correlated with increased risk for cancer [104]. DEK autoantibodies have been found in the serum and synovial fluid of patients with many different autoimmune disorders including juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), sarcoidosis, and rheumatoid arthritis [52]. JIA, formerly juvenile rheumatoid arthritis, is characterized by chronic inflammation in one or more joints and is the most common childhood rheumatoid-related condition [105]. SLE primarily affects women and is characterized by severe inflammation that is believed to be caused by a type I interferon mediated positive feedback loop with active B and T lymphocytes [106]. Sarcoidosis usually occurs in the lungs of patients suffering with this systemic granulomatous disease that is characterized by noncaseating granulomas that result from persistent inflammation of unknown origins [107].

DEK was first described as an autoantigen in JIA patients when the presence of DEK specific antibodies correlated with different subtypes of the condition, most frequently seen in pauciarticular onset JIA in 77% of tested patients. The presence of DEK antibodies in JIA patient serum and synovial fluid was later confirmed by several other groups; one revealed a similar percentage of anti-DEK(+) JIA patients at 57% [108, 109]. In addition to anti-DEK autoantibodies, which are produced by B cells, T cells may also become falsely activated in autoimmune diseases through the presentation of DEK peptides by HLA-A molecules. Specific DEK amino acid sequences (72–80, 163–171, and 155–153) can bind the HLA-A*0201 subclass associated with the pauciarticular subtype of JIA. This suggests that DEK may form complexes with class I MHC molecules which may provide a mechanism by which antigen presenting cells induce CD8+ stimulation to elicit inflammation events seen in JIA patients [110]. This is further supported in patients with the correlation between positivity for DEK antibodies and the presence of the class I HLA-A2 allele [108]. Furthermore, DEK can also be secreted by synovial macrophages, further compounding inflammatory pathogenesis. The C-terminal region of the secreted form of DEK, which is often acetylated, is recognized by IgG2 antibody complexes. These interactions demonstrate a second potential role for DEK in IgG-complement activation in the mediation of immune responses [111]. Additionally, multiallelic marker genotyping and SNP genotyping revealed that the 3′ UTR of DEK was associated with rheumatoid arthritis susceptibility, further supporting evidence that DEK may be a crucial component of arthritis related chronic inflammation [112].

Several early studies discovered anti-DEK antibodies in the serum of patients with SLE and/or sarcoidosis [108, 113, 114]. Wichmann et al. found that 10.4% of tested SLE patients had DEK specific autoantibodies in their serum. The presence of the anti-DEK antibodies was associated with older patients and fewer cutaneous manifestations [115]. Dong et al. provided a broad screening of sera from patients with an array of inflammation-related conditions. They identified elevated frequency of anti-DEK positivity not only in JIA, SLE, sarcoidosis, and rheumatoid arthritis patient sera but also in systemic sclerosis, polymyositis, and tuberculosis patient sera [52]. These studies illuminate the potentially broad role of DEK in inflammation-related functions and interactions during infection and immune responses. However, the role of DEK in these interactions can also have substantial implications in cancer biology and tumor microenvironments.

The multifunctionality of DEK in immune cells and cancer cells suggests a paradoxical outcome in tumor biology. As previously discussed, elevated DEK can promote oncogenic activities in infected and uninfected cells; however, DEK also displays an affinity for inducing immune responses in local areas of expression. There are several mechanisms by which DEK may mediate inflammation and tumor immunity responses in tumor microenvironments. These include (1) transcriptional regulation of antigen presenting molecules [116], (2) stimulation of T cells by epitope presentation [117, 118], and (3) secretion into extracellular matrix [44, 53]. First,
DEK has the potential to regulate class II MHC expression by interacting with NF-Y and binding Y-box promoter elements unique to MHC class II alleles [116]. This role as a transcriptional regulator could influence the presentation of tumor-related antigens to CD4+ T cells and thus contribute to adaptive immune responses targeting tumor cells. Second, DEK may be a tumor-associated antigen. Dendritic cells loaded with DEK-CAN AML associated fusion proteins can present DEK epitopes via class II MHC molecules and stimulate specific CD4+ T-cells in coculture [118]. The capacity of DEK to stimulate CD8+ T cells was also documented in vivo and in vitro [117]. In this study, DEK was the only oncogenic transcript identified multiple times in a screening of genes possibly involved in an immune response against neuroblastoma. In subsequent experiments, mice received a T cell stimulant and a Treg inhibitor to enable self-antigen specific immune responses. In vivo, this combination increases DEK-specific IgG antibodies found in the serum. In vitro, CD8+ T cells from these mice showed elevated activity when cocultured with DEK-loaded macrophages or neuroblastoma cells. Together these three studies implicate DEK as a tumor-associated antigen that may mediate interactions between lymphocytes and tumor cells. Third, and finally, DEK secretion by macrophages also has two major implications on potential tumor microenvironments. As a proinflammatory chemotactrant, secreted DEK can stimulate white blood cell migration, including neutrophils, CD8+ lymphocytes, and natural killer (NK) cells [44]. The implications for this activity in the context of tumorigenic microenvironments are poorly understood. While tumor-associated macrophages and neutrophils are primarily known to promote tumorigenesis [119], CD8+ T cells and NK cells are likely antitumor-mogenic [120, 121]. Secreted DEK can also be internalized by DEK-deficient HeLa cells, in a heparan sulfate-dependent process, where it can function as a nuclear oncprotein and rescue DEK depletion-induced DNA-damage repair and heterochromatin integrity [53]. Interestingly, macrophages are not the only cells to secrete DEK; conditioned media from HepG2 hepatocellular carcinoma cells were also found to contain DEK peptides [122, 123]. These results illuminate the potential role for extracellular DEK to stimulate tumor-associated immunological responses and promote intracellular oncogenic activity in neighboring epithelial cells within the tumor microenvironment.

6. DEK Regulates NFκB Transcriptional Activity

Through multiple mechanisms, DEK can regulate the activity of numerous oncogenic signal transduction pathways. These include p53 family members, p53 and ΔNp63, to inhibit apoptosis and promote proliferation, respectively, Wnt/β-catenin signaling to drive proliferation and invasion, Rho signaling to promote migration, mTOR activity to enhance cellular proliferation, and the NFκB pathway [38, 39, 41, 64, 124–127]. The nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) family of transcription factors regulates gene expression in response to a variety of external stress and inflammatory stimuli. The NFκB family includes RelA (p65), RelB, c-Rel, p100/p52 (NFκB2), and p105/p50 (NFκB1). These transcription factors are activated as a result of environmental stimuli that include cytokines like tumor necrosis factor alpha (TNFα), markers of microbial infection like lipopolysaccharide (LPS), T cell and B cell antigen receptors, and genotoxic stress including radiation and reactive oxygen species. The acute presence of these stress signals rapidly activates cell surface receptors, which eventually result in the activation of IkB kinase (IKK2) in a NEMO-dependent mechanism. IKK then phosphorylates IkB, which triggers its ubiquitination and degradation. The degradation of IkB thus releases its inhibitory binding of NFκB/RelA, permitting the nuclear translocation of the transcription factor complex, where it then binds to transcription cofactors to direct gene expression. In response to these acute stress stimuli, NFκB/Rel family members transcribe genes such as growth factors, inhibitors of apoptosis, and cytokines, primarily through RelA:RelA, c-Rel:p50, and RelA:p50 dimers [128]. This canonical NFκB pathway thus promotes cellular proliferation, inflammation, and immunity to survive the environmental stress. In contrast, the noncanonical NFκB pathway utilizes a NEMO-independent kinase complex that includes IKK1 and NFκB-inducing kinase (NIK) to respond to sustained developmental signals. This noncanonical pathway primarily utilizes RelB:p50 or RelB:p52 complexes, although RelA:p50 dimers may also be involved, to cause cell differentiation during development [129].

NFκB signaling is a crucial pathway involved in both inflammation and tumorigenesis, which is underscored by the finding that patients with chronic inflammatory conditions have an increased risk for developing cancer. The prosurvival functions of NFκB signaling promote tumor cell viability whereas the cytokines that are produced by NFκB transcriptional activity will alter the antitumor immune response. Furthermore, NFκB activity can promote angiogenesis and metastasis and has implications for genome stability [130]. Thus, the proproliferative and prosurvival canonical NFκB signaling pathway may be oncogenic if constitutively activated, which can occur through either activating mutations within the pathway or chronic exposure to cytokines from tumor associated macrophages within the microenvironment [130, 131]. However, the prodifferentiation function of NFκB signaling may be tumor suppressive. In fact, the oncogenic versus tumor suppressive functions of NFκB signaling may be context- and tissue-specific. For example, activated NFκB signaling has been documented in lymphoid malignancies and inflammation-associated colon cancer and other solid tumors. However, inactivated NFκB signaling through the loss of IKK proteins has also been linked to tumorigenesis, suggesting some tumor suppressive functions. These include genetic and chemically induced mouse tumor models and studies of squamous cell carcinomas of the skin, lungs, and head and neck [132, 133]. Interestingly, a recent report by Wang et al. suggests that NFκB signaling may begin as a tumor suppressive pathway in mouse embryonic fibroblasts (MEFs), by promoting cell senescence and maintaining genome stability, as determined using p65−/− MEFs.
NFκB signaling can then switch to a tumor promoting pathway as cells undergo transformation, such as the introduction of mutant Ras<sup>G12V</sup> into the MEFs, by allowing the transformed cells to avoid macropage-induced cell death and evading other antitumor immunity activities in vivo [134]. Thus, the role of NFκB signaling in tumorigenesis is complex and dynamic.

DEK has been identified as a downstream target of noncanonical NFκB signaling. In normal human dermal fibroblasts, the loss of noncanonical pathway members NFκB2 and RelB by siRNA resulted in decreased DEK mRNA and protein levels, which was associated with cellular senescence, in a p53-dependent mechanism [135]. The loss of p53 by shRNA restored DEK expression in NFκB2 and RelB-deficient cells and prevented senescence induced by the DEK depletion [135]. This suggests that p53 and noncanonical NFκB signaling converge on the DEK promoter to decide cell fate.

Previous reports have demonstrated that DEK can function as both transcription factor activator and corepressor [33, 125, 136–138]. Sammons et al. were the first to report on cause caspase-dependent apoptosis [38, 40–42, 140, 141] (and data not shown). Since the mechanism of apoptosis induced by extreme changes in DEK expression is unclear, studies regarding the activity of specific transcription factors in response to DEK expression levels should be approached with caution. However, the data still supports a role for DEK in modulating RelA transcriptional activity in canonical NFκB signaling.

Combined, the data suggest that DEK may provide a dose-dependent mechanism for controlling p65/RelA transcriptional activity in the canonical NFκB pathway (Figure 1). In extreme excess, DEK inhibits NFκB signaling, which may lead to decreased survival. However, tumorigenic (modestly upregulated) levels of DEK may promote NFκB transcriptional activity through direct interactions with p65/RelA on gene promoters to induce expression of antiapoptotic genes like c-IAP2 and prometastasis genes like IL-8. In contrast, the loss of DEK can upregulate NFκB activity through upstream regulation of IkBα, which may correlate with an inflammatory or immune response as suggested by MCP-1 expression. Taken together, DEK is an important regulator of NFκB signaling to direct expression of both tumorigenic and proinflammatory target genes.

### 7. Summary

There is a growing understanding of the complex relationship between the immune system, inflammation, and tumorigenesis. Chronic inflammation is a well-known risk factor for tumor development, especially with epithelial tissues. This is likely due to either the highly oxidative environment during inflammation that can cause DNA damage and/or the creation of a highly vascularized growth factor-rich microenvironment resulting in a tumor-promoting stroma [142]. Various factors induce chronic inflammation including persistent bacterial and viral infections, exposure to environmental pollutants, and inflammatory autoimmune diseases. In addition to the creation of the tumor-promoting environment due to the immune response described above, the molecules produced by the immune system, like ROS and TNFα, can activate intracellular signaling pathways in the neighboring epithelial cells. One such example is the NFκB pathway, which responds to inflammatory signals and promotes cell survival. When constitutively activated, such as what may occur with chronic inflammation, NFκB signaling can promote tumorigenesis.

Here, we describe an oncogenic protein that is critically involved in infection, inflammation, and tumorigenesis. The chromatin modeling DEK protein has numerous roles that promote inflammation. These include (1) promoting the life cycles and latent infection with oncogenic viruses like HPV and EBV, (2) increased expression upon exposure to environmental pollutants, potentially to promote DNA repair or cell survival, (3) being a potent self-antigen in chronic inflammatory autoimmune diseases like arthritis and lupus, and (4) functioning as a proinflammatory chemoattractant to promote the migration of white blood cells when secreted by activated macrophages. These functions, whether they result in DEK overexpression or the internalization of excess...
Figure 1: DEK-mediated regulation of NFκB pathway activity in a dose-dependent manner. As DEK expression increases (red), canonical NFκB transcriptional activity decreases (blue). (a) In the absence of DEK, there is increased phosphorylation of IκBα, which leads to its degradation and the translocation of p65/RelA to the nucleus where it transcribes proinflammatory target genes like MCP-1. (b) In cells with endogenous levels of DEK, possibly in both normal and transformed cells, DEK colocalization with p65 on target gene promoters is induced by TNFα treatment. This results in the expression of potentially oncogenic, prosurvival target genes like c-IAP2. However, it is unknown how variations in DEK levels within this group, such as the difference between normal and transformed cells, may impact NFκB activity and the subsequent expression of various target genes. (c) When DEK is substantially overexpressed beyond physiological levels, such as what may occur when overexpressing DEK in already high-expressing transformed cell lines, NFκB activity is inhibited, which may trigger cell death.

Figure 2: A summary of the roles of DEK in inflammation and tumorigenesis. DEK promotes inflammatory processes like persistent viral infection and autoimmune diseases, possibly through NFκB signaling (left). High DEK levels also promote tumor growth, metastasis, chemotherapeutic response, and an overall poor prognosis, which correlates with the activity of many oncogenic molecular mechanisms including Wnt/β-catenin, mTOR, Rho, and NFκB signaling as well as regulating expression of p53 family members (right). Chronic inflammation, supported by DEK expression, may promote tumorigenesis.
secreted DEK by neighboring epithelial cells, can promote DEK-induced tumorigenesis (Figure 2). Elevated intracellular DEK levels are oncogenic, resulting in increased proliferation, migration, and resistance to genotoxic agents via the perturbation of several signal transduction pathways. It is unclear how DEK mediates these pathogenic and oncogenic cellular and molecular functions, although it is likely due, in part, to its ability to alter chromatin accessibility and transcription factor function, thus deregulating the expression of numerous target genes. The downstream pathways that are affected by DEK protein levels and DEK-induced transcriptional deregulation include p53, Wnt/β-catenin, mTor, Rho, and NFκB signaling. Importantly, DEK can modulate the transcriptional activity of the NFκB pathway in response to proinflammatory signals like TNFα in what may be a dose- or context-specific mechanism. Combined, DEK can promote both chronic inflammation and tumorigenesis in a multifaceted manner and has been implicated in numerous disease processes. This suggests that limiting DEK levels may be a desirable way to treat both chronic inflammation, due to viral infection or autoimmune disease, and cancer.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] K. Warzocha, P. Ribeiro, J. Bienvenu et al., “Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome,” Blood, vol. 91, no. 10, pp. 3574–3581, 1998.

[2] E. M. El-Omar, M. Carrington, W. H. Chow et al., “Interleukin-1 polymorphisms associated with increased risk of gastric cancer,” Nature, vol. 404, no. 6776, pp. 398–402, 2000.

[3] W. H. Wang, J. Q. Huang, G. F. Zheng, S. K. Lam, J. Karlberg, and B. C.-Y. Wong, “Nivolumab in previously untreated melanoma without BRAF mutation,” The New England Journal of Medicine, vol. 372, pp. 320–330, 2015.

[4] C. Robert, G. V. Long, B. Brady et al., “Nivolumab and ipilimumab inuntreated melanoma without BRAF mutation,” The New England Journal of Medicine, vol. 372, pp. 320–330, 2015.

[5] M. J. Kang, K. M. Kim, J. S. Bae et al., “Tumor-infiltrating lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer,” PLoS ONE, vol. 7, no. 6, Article ID e38711, 2012.

[6] X. Guo, Y. Fan, R. Lang et al., “Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast,” Modern Pathology, vol. 21, no. 9, pp. 1101–1107, 2008.

[7] E. T. Chang, T. Zheng, E. G. Weir et al., “Aspirin and the risk of Hodgkin’s lymphoma in a population-based case-control study,” Journal of the National Cancer Institute, vol. 96, no. 4, pp. 316–325, 2004.

[8] L. M. Duncan, L. A. Richards, and M. C. Mihm Jr., “Increased mast cell density in invasive melanoma,” Journal of Cutaneous Pathology, vol. 25, no. 1, pp. 11–15, 1998.

[9] V. Alexiadis, T. Waldmann, J. Andersen, M. Mann, R. Knippers, and C. Gruss, “The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner,” Genes & Development, vol. 14, no. 11, pp. 1308–1312, 2000.
G. M. Kavanaugh, T. M. Wise-Draper, R. J. Morreale et al., “The human DEK oncogene regulates DNA damage response signaling and repair,” Nucleic Acids Research, vol. 39, no. 17, pp. 7465–7476, 2011.

T. M. Wise-Draper, H. V. Allen, E. E. Jones, K. B. Habash, H. Matsuo, and S. I. Wells, “Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions,” Molecular and Cellular Biology, vol. 26, no. 20, pp. 7506–7519, 2006.

M. S. Khodadoust, M. Verhaegen, F. Kappes et al., “Melanoma proliferation and chemoresistance controlled by the DEK oncoprotein,” Cancer Research, vol. 69, no. 16, pp. 6405–6413, 2009.

F. Kappes, C. Damoc, R. Knippers, M. Przybyski, L. A. Pinna, and C. Gruss, “Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK,” Cellular and Molecular Biology, vol. 24, no. 13, pp. 6011–6020, 2004.

N. Mor-Vaknin, A. Punturieri, K. Sitwala et al., “The DEK nuclear autoantigen is a secreted chemotactic factor,” Molecular and Cellular Biology, vol. 26, no. 24, pp. 9484–9496, 2006.

J. Cleary, K. V. Sitwala, M. S. Khodadoust et al., “p300/CBP-associated factor drives DEK into interchromatin granule clusters,” The Journal of Biological Chemistry, vol. 280, no. 36, pp. 31760–31767, 2005.

F. Kappes, J. Fahrer, M. S. Khodadoust et al., “DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress,” Molecular and Cellular Biology, vol. 28, no. 10, pp. 3245–3257, 2008.

H. E. Broxmeyer, N. Mor-Vaknin, F. Kappes et al., “Concise review: role of DEK in stem/progenitor cell biology,” Stem Cells, vol. 31, no. 8, pp. 1447–1453, 2013.

T. McGarvey, E. Rosonina, S. McCracken et al., “The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes,” Journal of Cell Biology, vol. 150, no. 2, pp. 309–320, 2000.

R. Babaei-Jadidi, N. Li, A. Saadeddin et al., “FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation,” The Journal of Experimental Medicine, vol. 208, no. 2, pp. 295–312, 2011.

H. le Hir, D. Gatfield, E. Izaurralde, and M. J. Moore, “The exon-junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay,” The EMBO Journal, vol. 20, no. 17, pp. 4987–4997, 2001.

L. M. M. Soares, K. Zanier, C. Mackereth, M. Sattler, and J. Valc˘arc˘el, “Intron removal requires proofreading of U2AF3′ splice site recognition by DEK,” Science, vol. 312, no. 5782, pp. 1961–1965, 2006.

X. Dong, J. Wang, F. N. Kabir et al., “Autoantibodies to DEK oncoprotein in human inflammatory disease,” Arthritis & Rheumatology, vol. 43, no. 1, pp. 85–93, 2000.

A. K. Saha, F. Kappes, A. Mundade et al., “Intercellular trafficking of the nuclear oncoprotein DEK,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 17, pp. 6847–6852, 2013.

N. Kondoh, T. Wakatsuki, R. Akihide et al., “Identification and characterization of genes associated with human hepatocellular carcinogenesis,” Cancer Research, vol. 59, no. 19, pp. 4990–4996, 1999.

R. A. Kroes, A. Jastrow, M. G. McLone et al., “The identification of novel therapeutic targets for the treatment of malignant brain tumors,” Cancer Letters, vol. 156, no. 2, pp. 191–198, 2000.

M. Sanchez-Carbayo, N. D. Socci, J. J. Lozano et al., “Gene discovery in bladder cancer progression using cDNA microarrays,”
A. K. Adams, G. E. Hallenbeck, K. A. Casper et al., “DEK expression is correlated with lymph node status,” Molecular Cancer Research, vol. 5, no. 9, pp. 881–890, 2007.

Q. Wu, Z. Li, H. Lin, L. Han, S. Liu, and Z. Lin, “DEK overexpression in uterine cervical cancers,” Pathology International, vol. 58, no. 6, pp. 378–382, 2008.

F. Kappes, M. S. Khodadoust, L. Yu et al., “DEK expression in melanocytic lesions,” Human Pathology, vol. 42, no. 7, pp. 932–938, 2011.

Y. Aalto, W. El-Rifai, L. Vilpo et al., “Distinct gene expression profiling in chronic lymphocytic leukemia with Ig23 deletion,” Leukemia, vol. 15, no. 11, pp. 1721–1728, 2001.

L. Lin, J. Piao, W. Gao et al., “DEK overexpression as an independent biomarker for poor prognosis in colorectal cancer,” BMC Cancer, vol. 13, article 366, 2013.

A. K. Adams, G. E. Hallenbeck, K. A. Casper et al., “DEK promotes HPV-positive and -negative head and neck cancer cell proliferation,” Oncogene, vol. 34, pp. 868–877, 2015.

J. P. Theurillat, N. D. Udeshi, W. J. Errington et al., “Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer,” Science, vol. 346, no. 6205, pp. 85–89, 2014.

M. S. Carro, F. M. Spiga, M. Quarto et al., “DEK expression is controlled by E2F and deregulated in diverse tumor types,” Cell Cycle, vol. 5, no. 11, pp. 1202–1207, 2006.

K. V. Sitwala, K. Adams, and D. M. Markovitz, “YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek–can promoter,” Oncogene, vol. 21, no. 57, pp. 8862–8870, 2002.

L. M. Privette Vinnedge, S. M. Ho, K. A. Wikenheiser-Brokamp, and S. I. Wells, “The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer,” PLoS ONE, vol. 7, no. 10, Article ID e46985, 2012.

A. J. Evans, B. L. Gallie, M. A. S. Jewett et al., “Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction,” The American Journal of Pathology, vol. 164, no. 1, pp. 285–293, 2004.

C. C. Chang, H. H. Lin, J. K. Lin et al., “FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients,” The International Journal of Biological Markers, vol. 30, no. 1, pp. e88–e95, 2015.

S. Liu, X. Wang, F. Sun, J. Kong, Z. Li, and Z. Lin, “DEK overexpression is correlated with the clinical features of breast cancer,” Pathology International, vol. 62, no. 3, pp. 176–181, 2012.

A. Deutzmann, M. Ganz, F. Schönenberger, J. Vervoorts, F. Kappes, and E. Ferrando-May, “The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress,” Oncogene, 2014.

E. Riveiro-Falkenbach and M. S. Soengas, “Control of tumorigenesis and chemoresistance by the DEK oncogene,” Clinical Cancer Research, vol. 16, no. 11, pp. 2932–2938, 2010.

J. Piao, Y. Shang, S. Liu et al., “High expression of DEK predicts poor prognosis of gastric adenocarcinoma,” Diagnostic Pathology, vol. 9, no. 1, article 67, 2014.

X. Wang, L. Lin, X. Ren et al., “High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer,” International Journal of Clinical and Experimental Pathology, vol. 7, pp. 5016–5023, 2014.

H. C. Yi, Y. L. Liu, P. You et al., “Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma,” Molecular Medicine Reports, vol. 11, no. 2, pp. 1318–1323, 2015.

T. M. Wise-Draper, H. V. Allen, M. N. Thobe et al., “The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7,” Journal of Virology, vol. 79, no. 22, pp. 14309–14317, 2005.

T. M. Wise-Draper, R. J. Morreale, T. A. Morris et al., “DEK proto-oncogene expression interferes with the normal epithelial differentiation program,” The American Journal of Pathology, vol. 174, no. 1, pp. 71–81, 2009.

T. M. Wise-Draper, A. R. Mintz-Cole, A. T. Morris et al., “Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo,” Cancer Research, vol. 69, no. 5, pp. 1792–1799, 2009.

T. M. Wise-Draper, A. R. Mintz-Cole, A. T. Morris et al., “Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo,” Cancer Research, vol. 69, no. 5, pp. 1792–1799, 2009.

J. C. Oancea, B. Rüster, R. Henschler, E. Puccetti, and M. Ruthardt, “The (6/9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation,” Leukemia, vol. 24, no. 11, pp. 1910–1919, 2010.

T. M. Wise-Draper, A. R. Mintz-Cole, A. T. Morris et al., “Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo,” Cancer Research, vol. 69, no. 5, pp. 1792–1799, 2009.

D. M. Ibrahim, E. Fjære, E. J. Lock et al., “Chronic consumption of farmed salmon containing persistent organic pollutants causes insulin resistance and obesity in mice,” PLoS ONE, vol. 6, no. 9, Article ID e25170, 2011.

V. Poli, “The role of CEBP isoforms in the control of inflamma- tory and native immunity functions,” The Journal of Biological Chemistry, vol. 273, no. 45, pp. 29279–29282, 1998.

D. A. Brenner, M. O’Hara, P. Angel, M. Chojkier, and M. Karin, “Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha,” Nature, vol. 337, no. 6208, pp. 661–663, 1989.

R. Grenningloh, B. Y. Kang, and I.-C. Ho, “Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses,”
